Nordic expansion LINK Medical has recently acquired CRST Oy to strengthen its Nordic footprint and clinical capabilities, signaling new collaboration opportunities with Finnland-based sites and cross-border regulatory services that can be leveraged to win multi-country studies.

Phase I focus The company now offers a complete range of clinical services from First-in-Human and early-phase studies through Phase IV, presenting opportunities to pitch early development programs and expanded Phase I/II trials across biotech and pharma clients.

Regulatory leadership With one of the largest regulatory teams in the Nordics and extensive regulatory services across pre-clinical to post-marketing, LINK Medical can target sponsors seeking robust regulatory pathways and faster approvals in Nordic markets.

Strategic partnerships Ongoing acquisitions and partnerships with biotech and pharma players, along with recent collaborations like Lipigon, indicate a proven track record in forming joint ventures and preferred CRO relationships for milestone-driven programs.

Sizable yet agile While the firm is mid-sized, revenue in the tens of millions and a broad service scope across regulatory, clinical, and market access positions it as an agile partner capable of handling mid-to-large programs with streamlined decision cycles.